Top

Published in:

Open Access 01-07-2018 | Original Contributions

Systemic Inflammation in Severe Obese Patients Undergoing Surgery for Obesity and Weight-Related Diseases

Authors: Wilson R. Freitas Jr., Luis Vicente Franco Oliveira, Eduardo A. Perez, Elias J. Ilias, Carina P. Lottenberg, Anderson S. Silva, Jessica J. Urbano, Manoel C. Oliveira Jr., Rodolfo P. Vieira, Marcelo Ribeiro-Alves, Vera L. S. Alves, Paulo Kassab, Fabio R. Thuler, Carlos A. Malheiros

Published in: Obesity Surgery | Issue 7/2018

Abstract

Background

Obesity is a worldwide disease related to genetic, environmental, and behavioral factors, and it is associated with high rates of morbidity and mortality. Recently, obesity has been characterized by a low-grade inflammatory state known as inflammome indicated by chronic increases in circulating concentrations of inflammatory markers. The purpose of this study was to evaluate the effect of weight loss induced by surgery for obesity and weight-related diseases on pro-inflammatory cytokine (TNF-α) and anti-inflammatory adipokine (adiponectin) levels, and on an adipose-derived hormone (leptin) in severely obese subjects.

Methods

This randomized, controlled trial involved 55 severe obese patients (50 women, age 18–63 years, and body mass index of 35.7–63 kg/m²) who underwent bariatric surgery (BS). Patients with a BMI > 65 kg/m² and clinical and mental instability, or significant and unrealistic expectations of surgery were excluded. Blood samples were collected during the fasting period to analyze tumor necrosis factor alpha (TNF-α), adiponectin, and leptin levels by enzyme-linked immunosorbent assay.

Results

At baseline, no significant difference was observed in the anthropometric, demographic, clinical characteristics and biochemistry and inflammatory markers between the control group (CG) and bariatric surgery group (BSG). The same finding was also observed when we compared the baseline variables to those at the 6-month follow-up in the CG. However, the same variables in the BSG group were significantly different between baseline and the 6-month follow-up after BS.

Conclusions

Weight loss induced by surgery for obesity and weight-related diseases reduced the inflammome state in severely obese patients.

World Health Organization: Obesity and overweight fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 04 Nov 2016.

Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7. https://doi.org/10.1001/jama.2012.39.CrossRefPubMed

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:i-xii, 1–253.

Mechanick JI, Garber AJ, Handelsman Y, et al. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642–8. https://doi.org/10.4158/EP12160.PS.CrossRefPubMed

Strasser B. Immune-mediated inflammation as a driver of obesity and comorbid conditions. Obesity (Silver Spring). 2017 Jun;25(6):987–8. https://doi.org/10.1002/oby.21872.CrossRef

Mangge H, Summers KL, Meinitzer A, et al. Obesity-related dysregulation of the tryptophan–kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity (Silver Spring). 2014;22(1):195–201. https://doi.org/10.1002/oby.20491.CrossRef

Pesquisa Nacional de Saúde 2013. Ministério do Planejamento, Orçamento e Gestão. Instituto Brasileiro de Geografia e Estatística–IBGE. 2014. Rio de Janeiro, RJ–Brasil. ISBN 978-85-240-4334-5.

Campos JM, Ramos AC, Cohen R. The importance of Brazilian Society of Metabolic and Bariatric Surgery and its interaction with the XXI World Congress of IFSO in Brazil. ABCD Arq Bras Cir Dig. 2016;29(Supl.1):1–2. https://doi.org/10.1590/0102-6720201600S10001.CrossRef

De Luca M, Angrisani L, Himpens J, et al. Indications for surgery for obesity and weight-related diseases: position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2016 Aug;26(8):1659–96. https://doi.org/10.1007/s11695-016-2271-4.CrossRefPubMedPubMedCentral

10.

Mancini MC, Melo ME. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndr. 2017;9(1):44. https://doi.org/10.1186/s13098-017-0242-0.CrossRefPubMedPubMedCentral

11.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9. https://doi.org/10.1016/j.jaci.2005.02.023.CrossRefPubMed

12.

Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(03):347–55. https://doi.org/10.1079/BJN20041213.CrossRefPubMed

13.

Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95(5):2111–9. https://doi.org/10.1172/JCI117899.CrossRefPubMedPubMedCentral

14.

Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409–15. https://doi.org/10.1172/JCI117936.CrossRefPubMedPubMedCentral

15.

Lundgren CH, Brown SL, Nordt TK, et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93(1):106–10. https://doi.org/10.1161/01.CIR.93.1.106.CrossRefPubMed

16.

Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12. https://doi.org/10.1038/35053000.CrossRefPubMed

17.

Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697–738. https://doi.org/10.1210/edrv.21.6.0415.CrossRefPubMed

18.

Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972–8. https://doi.org/10.1161/01.ATV.19.4.972.CrossRefPubMed

19.

Cigolini M, Targher G, Bergamo AI, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16(3):368–74. https://doi.org/10.1161/01.ATV.16.3.368.CrossRefPubMed

20.

Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 14;113(6):898–918. https://doi.org/10.1161/CIRCULATIONAHA.106.171016.CrossRefPubMed

21.

Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641. https://doi.org/10.1002/14651858.CD003641.pub4.CrossRef

22.

Sams VG, Blackledge C, Wijayatunga N, et al. Effect of bariatric surgery on systemic and adipose tissue inflammation. Surg Endosc. 2016;30(8):3499–504. https://doi.org/10.1007/s00464-015-4638-3.CrossRefPubMed

23.

Jimenez A, Casamitjana R, Flores L, et al. Longterm effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9. https://doi.org/10.1097/SLA.0b013e318262ee6b.CrossRefPubMed

24.

Moy J, Pomp A, Dakin G, et al. Laparoscopic sleeve gastrectomy for morbid obesity. Am J Surg. 2008;196(5):e56–9. https://doi.org/10.1016/j.amjsurg.2008.04.008.CrossRefPubMed

25.

Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52. https://doi.org/10.1056/NEJMoa066254.CrossRefPubMed

26.

Morinigo R, Casamitjana R, Delgado S, et al. Insulin resistance, inflammation, and the metabolic syndrome following Rouxen-Y gastric bypass surgery in severely obese subjects. Diabetes Care. 2007;30(7):1906–8. https://doi.org/10.2337/dc07-0189.CrossRefPubMed

27.

Arismendi E, Rivas E, Agustí A, et al. The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One. 2014;9(9):e107859. https://doi.org/10.1371/journal.pone.0107859.CrossRefPubMedPubMedCentral

28.

Chan AW; Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krlezˇa-Jeric´ K et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–207, 3, DOI: https://doi.org/10.7326/0003-4819-158-3-201302050-00583.

29.

Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report: National Institutes of Health. Obes Res. 1998; Suppl 2:51S–209S.

30.

Freitas Junior WR, Ilias EJ, Kassab P, et al. Assessment of the body composition and the loss of fat-free mass through bioelectric impedance analysis in patients who underwent open gastric bypass. Sci World J. 2014;2014:843253.CrossRef

31.

Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20(5):623–32. https://doi.org/10.1007/s11695-010-0103-5.CrossRefPubMed

32.

Lasselin J, Magne E, Beau C, et al. Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgery-induced weight loss. J Clin Endocrinol Metab. 2014 Jan;99(1):E53–61. https://doi.org/10.1210/jc.2013-2673.CrossRefPubMed

33.

Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5. https://doi.org/10.1001/jama.282.22.2131.CrossRefPubMed

34.

Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF- and IL-6. Diabetes Res Clin Pract. 2005;69(1):29–35. https://doi.org/10.1016/j.diabres.2004.11.007.CrossRefPubMed

35.

Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res. 2012;61(8):789–807. https://doi.org/10.1007/s00011-012-0473-3.CrossRefPubMed

36.

Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm. 2010;2010:513948–20. https://doi.org/10.1155/2010/513948.CrossRef

37.

Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196–200. https://doi.org/10.1210/jcem.82.12.4450.CrossRefPubMed

38.

Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25. https://doi.org/10.1172/JCI28898.CrossRefPubMedPubMedCentral

39.

Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671–4. https://doi.org/10.1161/01.CIR.0000055188.83694.B3.CrossRefPubMed

40.

van Dielen FM, van't Veer C, Schols AM, et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25(12):1759–66. https://doi.org/10.1038/sj.ijo.0801825.CrossRefPubMed

41.

Finck BN, Johnson RW. Tumor necrosis factor (TNF)-alpha induces leptin production through the p55 TNF receptor. Am J Physiol Regul Integr Comp Physiol. 2000;278(2):R537–43. https://doi.org/10.1152/ajpregu.2000.278.2.R537.CrossRefPubMed

42.

Zhao T, Hou M, Xia M, et al. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol. 2005;238(1):19–30. https://doi.org/10.1016/j.cellimm.2005.12.002.CrossRefPubMed

43.

Mallipedhi A, Prior SL, Barry JD, et al. Changes in inflammatory markers after sleeve gastrectomy in patients with impaired glucose homeostasis and type 2 diabetes. Surg Obes Relat Dis. 2014;10(6):1123–8. https://doi.org/10.1016/j.soard.2014.04.019.CrossRefPubMed

44.

Rość D, Adamczyk P, Boinska J, et al. CRP, but not TNF-α or IL-6, decreases after weight loss in patients with morbid obesity exposed to intensive weight reduction and balneological treatment. J Zhejiang Univ Sci B. 2015;16(5):404–11. https://doi.org/10.1631/jzus.B1400219.CrossRefPubMedPubMedCentral

45.

Ibrahim NE, Januzzi Jr JL, Magaret CA, et al. A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease. J Am Coll Cardiol. 2017;69(9):1147–56. https://doi.org/10.1016/j.jacc.2016.12.021.CrossRefPubMed

46.

Berstein LM, Poroshina TE, Turkevich EA, et al. Features of endometrial cancer in patients with 'metabolically healthy' versus 'standard' obesity: the decreasing frequency of metabolically healthy obesity. Future Sci OA. 2015;1(4):FSO68. https://doi.org/10.4155/fso.15.68.CrossRefPubMedPubMedCentral

47.

Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev. 2013;14(12):939–49. https://doi.org/10.1111/obr.12064.CrossRefPubMed

48.

Thomsen SB, Rathcke CN, Jørgensen NB, et al. Effects of Roux-en-Y gastric bypass on fasting and postprandial levels of the inflammatory markers YKL-40 and MCP-1 in patients with type 2 diabetes and glucose tolerant subjects. J Obes. 2013;2013:361781–10. https://doi.org/10.1155/2013/361781.CrossRefPubMedPubMedCentral

49.

Ray I, Mahata SK, De RK. Obesity: an Immunometabolic perspective. Front Endocrinol. 2016;7:157.CrossRef

50.

Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications centric approach. Endocr Pract. 2013;19(5):864–74. https://doi.org/10.4158/EP13263.RA.CrossRefPubMedPubMedCentral

51.

Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, et al. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114(3):183–94. https://doi.org/10.1080/13813450802181047.CrossRefPubMed

Title: Systemic Inflammation in Severe Obese Patients Undergoing Surgery for Obesity and Weight-Related Diseases
Authors: Wilson R. Freitas Jr.
Luis Vicente Franco Oliveira
Eduardo A. Perez
Elias J. Ilias
Carina P. Lottenberg
Anderson S. Silva
Jessica J. Urbano
Manoel C. Oliveira Jr.
Rodolfo P. Vieira
Marcelo Ribeiro-Alves
Vera L. S. Alves
Paulo Kassab
Fabio R. Thuler
Carlos A. Malheiros
Publication date: 01-07-2018
Publisher: Springer US
Published in: Obesity Surgery / Issue 7/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-017-3104-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Systemic Inflammation in Severe Obese Patients Undergoing Surgery for Obesity and Weight-Related Diseases

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Predictors of Postoperative Urinary Tract Infection After Bariatric Surgery

Predicting remission of diabetes post metabolic surgery: a comparison of ABCD, diarem, and DRS scores

Closed Incision Negative-Pressure Therapy (ciNPT) Reduces Minor Local Complications in Post-bariatric Abdominoplasty Body Contouring: a Retrospective Case-Control Series

Response to a Letter to the Editor Re: Detecting Bile Reflux—the Enigma of Bariatric Surgery

Factors Predicting Length of Stay Following Bariatric Surgery: Retrospective Review of a Single UK Tertiary Centre Experience

Efficacy of Forced-Air Warming to Prevent Perioperative Hypothermia in Morbidly-Obese Versus Non-obese Patients